Elsevier

The Lancet Oncology

Volume 16, Issue 7, July 2015, Pages e322-e332
The Lancet Oncology

Review
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

https://doi.org/10.1016/S1470-2045(15)00076-5Get rights and content

Summary

The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.

Introduction

Primary CNS lymphomas are extranodal, malignant non-Hodgkin lymphomas of the diffuse large B-cell type that are confined to the brain, eyes, leptomeninges, or spinal cord, in the absence of systemic lymphoma. Primary CNS lymphomas are estimated to account for up to 1% of all lymphomas, 4–6% of all extranodal lymphomas, and about 3% of all CNS tumours.1 After a continuous rise in the incidence of primary CNS lymphoma during the 1980s and 1990s, epidemiological data in high-income countries show a decrease in incidence, particularly among young patients with AIDS.2 By contrast, the incidence of primary CNS lymphoma continues to rise in elderly patients, who represent most patients in immunocompetent populations.3, 4, 5

Although the prognosis of primary CNS lymphoma remains poor, it has substantially improved in the past two decades as a result of better treatment strategies with a curative aim. However, treatment of this disease remains challenging because, despite high chemosensitivity and radiosensitivity, remissions are frequently of short duration. The blood–brain barrier limits the access of many drugs to the CNS. Furthermore, elderly patients are at especially high risk for the development of severe neurotoxic effects related to treatment.

Optimum treatment recommendations result mainly from retrospective series or single-arm phase 2 studies. Only three completed randomised trials are available for primary CNS lymphoma: one phase 3 and two phase 2 trials.6, 7, 8 The objective of this guideline is to provide clinicians with evidence-based recommendations and consensus expert opinions for the management of patients with this disease. The guidelines focus exclusively on immunocompetent populations, which represent most patients. Primary CNS lymphoma in immunodeficient patients and rare, indolent, low-grade lymphomas that occur mainly in the CNS have a distinct pathogenesis with separate diagnostic and therapeutic implications, and will be subject to specific guidelines, beyond the scope of this Review.

Section snippets

Search strategy and selection criteria

The task force was established in 2013 under the auspices of the European Assocation for Neuro-Oncology and represents European-based medical experts from eleven countries. The task force included specialists in the management of primary CNS lymphoma—including neurologists, haematologists, medical oncologists, neurosurgeons, pathologists, ophthalmologists, and radiation oncologists. Based on best available evidence from literature review, the writing group (EB, JB, AFH, KH-X, MP, RR, US, TS,

General recommendations

Consensus statements and recommendations were given for the following aspects of primary CNS lymphoma: pathology, genetics, clinical presentation, diagnostic confirmation, neuropathological changes of corticosteroid-treated primary CNS lymphoma, neuroimaging, cerebrospinal fluid analyses, vitreous analyses, staging, prognostic factors, response criteria to treatment, and treatment-related neurotoxic effects. Consensus statements and recommendations for the general approach to patients with

Surgery

Although few data are available in the scientific literature, surgery has traditionally been deemed to have no role in the treatment of primary CNS lymphoma. This widely adopted opinion is based on small retrospective series, the results of which suggest no clear benefits in the outcome of surgical resection when used as a sole treatment, compared with supportive care (class IIIb)9 and compared with evidence from biopsy samples from patients who received postoperative chemotherapy or

Systemic chemotherapy

The CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen routinely used for widespread non-Hodgkin lymphomas induces responses of brief duration in patients with primary CNS lymphoma. CHOP added to radiotherapy has likewise not improved patient survival in prospective trials (class IIb).14, 15, 16 This inefficacy is probably because the metabolite of cyclophosphamide, phosphoramide mustard, and doxorubicin are not able to cross the blood–brain barrier and therefore eradicate

Intrathecal chemotherapy

Chemotherapeutic drugs given intrathecally have not been prospectively studied. Therefore, their clinical effectiveness in primary CNS lymphoma is controversial. Results of three retrospective studies30, 31, 32 showed that patients given high-dose methotrexate did not benefit from the additional treatment with methotrexate and cytarabine given intrathecally (class IIIb). By contrast, results from two consecutive single-arm trials33, 34 using the same systemic polychemotherapy regimen suggested

Rituximab

The anti-CD20 antibody rituximab has poor CNS penetration because of its large size. Therefore, the highest concentration and resultant efficacy of rituximab probably occurs during the early treatment phase when the integrity of the blood–brain barrier is reduced at the location of the contrast-enhancing tumours. The effect of rituximab when used as monotherapy in patients with primary CNS lymphoma was assessed in a study in which 12 patients with refractory or relapsed primary CNS lymphoma

Radiotherapy

Because of the microscopically diffuse and multifocal nature of primary CNS lymphoma, radiotherapy is used to target the whole brain and the eyes. Despite a high response rate of around 50%, radiotherapy, when used alone, does not provide a substantial survival benefit in patients with primary CNS lymphoma, with a median overall survival of 10–18 months and 5-year overall survival of 5%. A phase 2 trial44 that used radiotherapy as first-line treatment was done by the Radiation Therapy Oncology

Consolidation radiotherapy

Although not formally compared in a randomised trial, results of several studies18, 45, 46, 47, 48, 49, 50, 51, 52, 53 suggest that the combination of high-dose methotrexate with radiotherapy is better than radiotherapy alone, in terms of increasing the proportion of long-term survivors (5-year survival 20–50%) (class IIb, class IIIa, class IIIb) and overall survival by two to four times (median 30–72 months). By contrast with extracerebral non-Hodgkin lymphoma, the optimum dose of

Reduced-dose consolidation radiotherapy

Since not giving consolidation WBRT for patients with complete response to chemotherapy is controversial, reduced-dose WBRT is an alternative approach, particularly for patients younger than 60 years who are at a lower risk of developing neurotoxic effects. In a subset analysis65 from a phase 2 trial that included 25 patients younger than 60 years who achieved a complete response after initial chemotherapy and received either 45 Gy or 30·6 Gy as consolidation treatment, patients who received

High-dose chemotherapy, myeloablative conditioning, and autologous stem-cell transplantation

High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is the standard treatment for chemosensitive systemic relapsing diffuse large B-cell lymphomas. However, there is only one multicentre phase 2 trial67 investigating this treatment in patients with relapsed or refractory primary CNS lymphoma, in which a thiotepa, busulfan, cyclophosphamide conditioning regimen was used, followed by ASCT. 27 (63%) of 43 patients completed the full HDC-ASCT procedure, of whom 60% achieved

Elderly patients

Although the definition of elderly is non-uniform within the literature, studies that have assessed prognostic factors have consistently correlated older age (over 50 or 60 years) with poorer outcome (appendix). Furthermore, older age (greater than 60 years) was associated with a higher risk of neurotoxic effects of chemoradiation (appendix). Therefore, 60 years of age was used as a cutoff to define the elderly population in most of the studies that we examined.

Four prospective studies37, 64, 77

Salvage treatment

About a third of patients with primary CNS lymphoma will present with disease that is refractory to first-line treatment and half of responders will relapse despite the high proportion of patients who respond to initial treatment. The prognosis of progressive or relapsed primary CNS lymphoma is poor, with few treatment options. Salvage treatments for patients with relapsed or refractory primary CNS lymphoma depend on age, performance status, site of relapse within the CNS, previous treatments,

Conclusion

Our guidelines represent the state of knowledge at the time of writing. The European Association for Neuro-Oncology website will provide future updates on these guidelines.

References (100)

  • L Lowry et al.

    Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial

    Radiother Oncol

    (2011)
  • AJ Ferreri et al.

    Whole-brain radiotherapy in primary CNS lymphoma

    Lancet Oncol

    (2011)
  • AJ Ferreri et al.

    Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy

    Int J Radiat Oncol Biol Phys

    (2011)
  • T Kiefer et al.

    Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study

    Ann Oncol

    (2012)
  • G Illerhaus et al.

    High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study

    Ann Oncol

    (2009)
  • NN Laack et al.

    Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51

    Int J Radiat Oncol Biol Phys

    (2006)
  • K Jahnke et al.

    High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

    Ann Oncol

    (2005)
  • L Fischer et al.

    Prospective trial on topotecan salvage therapy in primary CNS lymphoma

    Ann Oncol

    (2006)
  • PM Kluin et al.

    Primary diffuse large B-cell lymphoma of the CNS

  • NS Kadan-Lottick et al.

    Decreasing incidence rates of primary central nervous system lymphoma

    Cancer

    (2002)
  • EM Bessell et al.

    Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma

    J Neurooncol

    (2011)
  • JL Villano et al.

    Age, gender, and racial differences in incidence and survival in primary CNS lymphoma

    Br J Cancer

    (2011)
  • BP O'Neill et al.

    The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma

    Am J Hematol

    (2013)
  • JM Henry et al.

    Primary malignant lymphomas of the central nervous system

    Cancer

    (1974)
  • B Bataille et al.

    Primary intracerebral malignant lymphoma: a report of 248 cases

    J Neurosurg

    (2000)
  • R Lai et al.

    Primary CNS lymphoma: a whole-brain disease?

    Neurology

    (2002)
  • M Weller et al.

    Surgery for primary CNS lymphoma? Challenging a paradigm

    Neuro Oncol

    (2012)
  • C Schultz et al.

    Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD) for PCNSL: initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06

    J Clin Oncol

    (1996)
  • GM Mead et al.

    A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy

    Cancer

    (2000)
  • S Hiraga et al.

    Rapid infusion of high-dose methotrexate resulting in enhanced penetration into CSF and intensified tumour response in PCNSL

    J Neurosurg

    (1999)
  • J Glass et al.

    Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome

    J Neurosurg

    (1994)
  • PG Morris et al.

    Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome

    J Clin Oncol

    (2013)
  • U Herrlinger et al.

    German Cancer Society Neuro-Oncology Working Group NOA-03 multicentre trial of single agent high dose methotrexate for primary CNS lymphoma

    Ann Neurol

    (2002)
  • T Batchelor et al.

    Treatment of primary cerebral lymphoma with methotrexate and deferred radiotherapy: report of NABTT 96-07

    J Clin Oncol

    (2003)
  • N Bergner et al.

    Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)

    Cochrane Database Syst Rev

    (2012)
  • JL Rubenstein et al.

    Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)

    J Clin Oncol

    (2013)
  • AJ Ferreri et al.

    Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination

    Oncologist

    (2011)
  • ML Slevin et al.

    Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid

    J Clin Oncol

    (1983)
  • EA Neuwelt et al.

    Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function

    J Clin Oncol

    (1991)
  • LD McAllister et al.

    Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma

    Neurosurgery

    (2000)
  • L Angelov et al.

    Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience

    J Clin Oncol

    (2009)
  • AJ Ferreri et al.

    MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years

    Neurology

    (2014)
  • AJ Ferreri et al.

    Multicenter study of treatment of primary CNS lymphoma

    Neurology

    (2002)
  • RB Khan et al.

    Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

    J Neurooncol

    (2002)
  • M Sierra Del Rio et al.

    Prophylactic intrathecal chemotherapy in primary CNS lymphoma

    J Neurooncol

    (2012)
  • H Pels et al.

    Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy

    J Clin Oncol

    (2003)
  • H Pels et al.

    Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

    J Neurooncol

    (2009)
  • TT Batchelor et al.

    Rituximab monotherapy for patients with recurrent primary CNS lymphoma

    Neurology

    (2011)
  • MC Chamberlain et al.

    High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

    Neuro Oncol

    (2010)
  • S Mappa et al.

    Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy

    Hematol Oncol

    (2013)
  • Cited by (310)

    View all citing articles on Scopus
    View full text